NexgenRx Inc. (NEGXF)
OTC GREY OTC GREY Primary 
NexgenRx Announces Third Quarter Results and Declaration of Divdend
TORONTO, ON / ACCESSWIRE / November 25, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the third quarter ended September 30, 2024, with quarterly revenue increasing to $4,158,667 in Q3 2024 and increased positive EBITDA of $446,448.
NexgenRX Announces Director Re-Appointment
TORONTO, ON / ACCESSWIRE / October 7, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the re-appointment of Charles Burns to its Board of Directors effective immediately.
NexgenRx Announces New Director
TORONTO, ON / ACCESSWIRE / October 1, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the appointment of Linda Brennan to its Board of Directors effective immediately.
NexgenRx Announces Second Quarter Results, With Over 19% Revenue Growth and Positive EBITDA
TORONTO, ON / ACCESSWIRE / August 15, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the second quarter ended June 30, 2024, with quarterly revenue increasing to $4,084,839, and increased positive EBITDA of $376,500, resulting in a continued strong cash position for the Company.
NexgenRx Announces Share Issuances Under Consulting Agreement
TORONTO, ON / ACCESSWIRE / July 18, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the issuance of an aggregate of 195,312 common shares at a price of $0.32 in respect of the fourth quarterly equity payment under the Company's previously announced Consulting Agreement with PBM Management Services (for details, see the Company's news release dated August 21, 2023), as all services required in respect of such payments have been provided in full.
NexgenRx Announces Declaration of Dividend
NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares.
NexgenRx Announces First Quarter Results, with 24% Revenue Growth and Record Earnings
TORONTO, ON / ACCESSWIRE / May 17, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the first quarter ended March 31, 2024, with revenue of $4,292,731, Net Income of $460,949 and EBITDA of $770,837.
NexgenRx Announces Annual Meeting Results
TORONTO, ON / ACCESSWIRE / May 16, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the results of its annual and special meeting (the "Meeting") of shareholders, which was held on Thursday, May 16, 2024.
